The Tisch Cancer Institute at Mount Sinai | Strategic Alliance Partners

May 16, 2024

Sundar Jagannath, MBBS, discusses takeaways from the FDA’s ODAC consensus on safety considerations with cilta-cel in relapsed/refractory multiple myeloma.

May 14, 2024

Sundar Jagannath, MBBS, discusses the safety of linvoseltamab in relapsed/refractory multiple myeloma.

May 13, 2024

Following the consensus that the risk-benefit assessments for the proposed indications for cilta-cel and ide-cel were favorable during the March 15, 2024, FDA ODAC meeting, both BCMA-targeted CAR T-cell therapies received approvals moving them up in the treatment paradigm for relapsed or refractory multiple myeloma.

May 03, 2024

Sundar Jagannath, MBBS, discusses the patient population evaluated in the LINKER-MM1 trial of linvoseltamab in relapsed/refractory multiple myeloma.

April 25, 2024

Sundar Jagannath, MBBS, discusses linvoseltamab and expands on key efficacy and safety findings from the LINKER-MM1 trial in patients with relapsed/refractory multiple myeloma.

April 25, 2024

Sundar Jagannath, discusses the potential role for linvoseltamab in relapsed/refractory multiple myeloma.

April 19, 2024

Sundar Jagannath, MBBS, discusses the mechanism of action and tolerability of linvoseltamab in patients with relapsed/refractory multiple myeloma.

April 08, 2024

Linvoseltamab elicited responses with acceptable safety in patients with relapsed/refractory multiple myeloma, including difficult-to-treat subsets

April 02, 2024

Dmitriy Zamarin, MD, PhD, discusses the most recent advances in gynecologic cancer management, particularly in endometrial cancer.

March 29, 2024

Matthew Galsky, MD, discusses the significance of the FDA approval of frontline nivolumab plus chemotherapy patients with metastatic urothelial carcinoma.

March 29, 2024

Dmitriy Zamarin, MD, PhD, highlights key changes and ongoing research across the endometrial, ovarian, and cervical cancer realms.

March 19, 2024

Joshua Richter, MD, discusses ongoing or upcoming research with bispecific antibodies in relapsed/refractory multiple myeloma.

March 19, 2024

In a trial led by the Icahn School of Medicine at Mount Sinai, rusfertide demonstrated the ability to control the overproduction of RBCs in polycythemia vera.

March 14, 2024

A study sheds light on how immune genetics influence lung cancer risk, potentially paving the way for enhanced prevention strategies and screening.

February 27, 2024

Rusfertide displayed activity in phlebotomy-dependent polycythemia vera.

February 23, 2024

The FDA has determined that sufficient criteria have been met to withdraw the approval for melphalan flufenamide in patients with multiple myeloma.

February 15, 2024

Matthew Galsky, MD, discusses the significance of the FDA approval of enfortumab vedotin plus pembrolizumab as a first-line regimen in urothelial cancer.

February 12, 2024

Matthew Galsky, MD, discusses the FDA approval of enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.

February 12, 2024

Dr Galsky discusses the FDA approval of enfortumab vedotin plus pembrolizumab for patients with locally advanced or metastatic urothelial cancer.

January 11, 2024

John Mascarenhas, MD, discusses the potential advantages of utilizing selinexor with ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.